Adjunct Senior Research Fellow
Pfizer Global Research and Development
Pfizer, Inc., retired
Dr. Lipinski’s current research interests are: analysis and
investigation of drug-like properties; issues related to aqueous and DMSO drug
solubility; design and protocol development of combinatorial libraries; issues
related to compound storage in DMSO; exact compound batch mode searching and
computational ADME prediction. In addition to scientific advisory board
positions, he is the author of over 100 papers / presentations and 17 issued
U.S. patents. He is the originator of the rule of 5, a widely used filter for
drug like properties. He is a member of the editorial board of JPS and a member
of: the medicinal chemistry section ACS; PDD section AAPS, EUFEPS and the
Society for Biomolecular Screening.
Manager Basic Biological Support
Compound Management Group
Worked at Merck for over 23 years, primarily in the distribution of Natural
Products and Chemical Compounds.
New Leads Chemistry
Bristol-Myers Squibb Company
Dr. Sofia is Group Director of New Leads Chemistry at Bristol-Myers Squibb
where he is responsible for Lead Discovery and Program Support Combinatorial
Chemistry, External Compound Acquisition, Compound Management, Isolation
Chemistry, Biocatalysis and Cheminformatics functions.
Prior to joining BMS Dr. Sofia was Vice President of Chemistry at Intercardia
Research Labs (formerly Transcell Technologies) (1993-1999), where he directed
research in the areas of infectious diseases drug discovery and combinatorial
chemistry technology development. Prior to joining Transcell Technologies, Dr.
Sofia was Research Investigator and Project Leader at Lilly Research Labs, Eli
Lilly & Co. (1989-1993) in the area of inflammation research. As a Research
Investigator at the Squibb Institute for Medical Research, E. R. Squibb
(1986-1989), Dr. Sofia focused in the area of atherosclerosis drug discovery.
Dr. Sofia did his postdoctoral training in synthetic organic chemistry as an
NIH fellow at Columbia University (1984-1986) after receiving his Ph.D. in
organic chemistry from the University of Illinois, Urbana-Champaign (1984). Dr.
Sofia received his B.A. degree in chemistry from Cornell University (1980).
Dr. Sofia is on the editorial boards of Solid Phase Organic Synthesis,
Current Drug Targets Infectious Disease and Expert Opinion on Therapeutic
Targets. He has authored 56 publications and is an inventor on 20 patents.
Bristol-Myers Squibb Company
Timothy Spicer has been employed at Bristol-Myers Squibb Co. located in
Wallingford, Connecticut for more than eight years and is currently a Research
Scientist in the Department of Lead Discovery and Profiling. Prior to his
current position, he also worked in the Discovery Technologies department as
well as Infectious Diseases Department at BMS. Timothy received his educational
training at the SUNY Health Science Center at Syracuse, New York. He has
authored multiple publications and patents germane to his area of research.
Timothy works across multiple organizations and departments as part of a team
that implements assays and supports screening on fully automated platforms. He
is recognized at BMS and by collaborators as a leader in evaluating new
technologies for the purpose of making UHTS the standard.